Abstract
Pakistan, a dengue endemic country has encountered several outbreaks during the past decade. The current study aimed to explore the serotype and genomic diversity of dengue virus responsible for the 2022 outbreak in Pakistan. During August-October 2022, blood samples (n=436) were collected from dengue patients, among which 64.4% (n=281) were positive based on RT-PCR. A subset of DENV-2 and DENV-1 samples were further subjected to whole-genome sequencing. In terms of gender and age, dengue infection was more prevalent in male patients (62.9%) with more adults (77.5%) being infected. Moreover, serotyping revealed DENV-2 to be most predominant serotype (64%; n=180), followed by DENV-1 (35.2%; n=99) and DENV-3 (0.35%; n=1). Phylogenetic analysis of sequenced samples indicates that all the samples (n=8) belong to the DENV-2 Cosmopolitan genotype, falling within a single monophyletic clade that is closely related to sequences from China and Singapore in 2018. Dengue virus dynamics reported in the current study warrants large scale genomic surveillance in order to better respond to future outbreaks.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by Institutional Review Board of National Institute of Health, Islamabad, Pakistan.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
